Skip to content
DataLookout
Menu

NCT07926308

Real-world Outcome of Zongertinib in Japan (J-HERZ)

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Real-world overall response rate (rwORR) in the zongertinib 1L group
Timeframe: up to 4.6 years

Secondary (6)

rwORR in the zongertinib 2L group
rwORR in the zongertinib 3L group
Real world disease control rate (rwDCR) in the zongertinib 1L, 2L, and 3L groups
Real world progression-free survival (rwPFS) in the zongertinib 1L, 2L, and 3L group
Real world overall survival (rwOS) in the zongertinib 1L, 2L, and 3L group
Show 1 moreShow less
Real world time-to-treatment failure (rwTTF) in the zongertinib 1L, 2L, and 3L group

Arms and interventions

Zongertinib first-line treatment (1L) group

Japanese patients with human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC) have received their first systemic anticancer therapy for metastatic or locally advanced NSCLC.

Zongertinib second-line treatment (2L) group

Japanese patients with HER2-mutated NSCLC have received their systemic anticancer therapy administered after one prior line of systemic therapy for metastatic or locally advanced NSCLC.

Zongertinib third-line treatment (3L) group

Japanese patients with HER2-mutated NSCLC have received their systemic anticancer therapy administered after two prior lines of systemic therapy for metastatic or locally advanced NSCLC.

Drugs: Zongertinib

Sites

1 site in 1 country

  • Nippon Boehringer Ingelheim Co., Ltd.Tokyo, Japan